← Eichor
Study identifier: NCT06081244 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

Condition: Triple Negative Breast Cancer  ·  Sponsor: West German Study Group

PhasePhase 3
Planned participants348
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

TNBC is known for poor prognosis, aggressive patterns of disease, and significant molecular heterogeneity. (Neo)adjuvant chemotherapy (NACT) is standard of care in all node-positive and in node-negative patients with a tumour size \>5 mm according to current National Comprehensive Cancer Network (NCCN) guidelines. However, TNBC patients with lower stage disease do clearly have a better prognosis compared to more advanced stages. Patients with stage I-II node-negative disease have 3-5 year iDFS rates of 80-90% (with majority of relapses within the first three years) as shown in several trials.Although survival results appear much better in the lower vs. higher stages, there is a high clinical need in this most common group of TNBC patients in Western Europe and USA.

This description comes directly from the study's public registry record.

Talk to the study team

Oleg Gluz, PD Dr.  ·  +492161566230  ·  oleg.gluz@wsg-online.com

Anja Braschoß  ·  +4917682119153  ·  anja.braschoss@wsg-online.com

Always discuss trial participation with your own doctor first.

Locations (42)

Stadtklinik Baden-Baden / BrustzentrumBaden-Baden, Baden-Wurttemberg, GermanyRecruiting
Kliniken BöblingenBöblingen, Baden-Wurttemberg, GermanyRecruiting
Praxis für interdisziplinäre Onkologie & HämatologieFreiburg im Breisgau, Baden-Wurttemberg, GermanyRecruiting
SLK Kliniken Heilbronn, FrauenklinikHeilbronn, Baden-Wurttemberg, GermanyActive Not Recruiting
Universitätsklinikum TübingenTübingen, Baden-Wurttemberg, GermanyRecruiting
Universitätsklinikum UlmUlm, Baden-Wurttemberg, GermanyRecruiting
GRN Klinik WeinheimWeinheim, Baden-Württembergs, GermanyRecruiting
Hämatologie-Onkologie im Zentrum MVZ GmbHAugsburg, Bavaria, GermanyRecruiting
Universitätsklinikum Augsburg A.ö.R.Augsburg, Bavaria, GermanyRecruiting
Rotkreuzklinikum MünchenMünchen, Bavaria, GermanyActive Not Recruiting
DBZ Onkologie GmbHBerlin, Brandenburg, GermanyNot Yet Recruiting
Klinikum Ernst von Bergmann gGmbHPotsdam, Brandenburg, GermanyRecruiting

+ 30 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06081244